{
    "nct_id": "NCT03694522",
    "official_title": "FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1",
    "inclusion_criteria": "* Histologically documented gastric or gastroesophageal junctional adenocarcinoma (not amenable to curative therapy)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Adequate hematological, liver and kidney function. Measurable or non-measurable, but evaluable disease using RECIST v1.1\n* Fibroblast growth factor receptor 2b (FGFR2b) overexpression as determined by a centrally performed immunohistochemistry tissue test and/or FGFR2 gene amplification as determined by a centrally performed circulating tumor deoxyribonucleic acid (ctDNA) blood based assay\n* Candidate for mFOLFOX6 chemotherapy\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Untreated or symptomatic central nervous system (CNS) metastases\n* Clinically significant cardiac disease,\n* Peripheral sensory neuropathy >/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2\n* Active infection requiring systemic treatment\n* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection\n* Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway\n* Known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer\n* Known positivity for human epidermal growth factor receptor 2 (HER2)\n* Women who are pregnant or breastfeeding\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}